Categories: Press-Releases

$50+ Billion Clinical Trials Markets by Phase, Service Type, Therapy Area, and Application – Global Forecast to 2026 – ResearchAndMarkets.com


DUBLIN–()–The “Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) – Global Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.

The clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period, owing to increasing numbers of clinical trials, rising prevalence of orphan & rare diseases and high cost of in-house drug development.

“By service type, the laboratory services segment accounted for the largest share of the clinical trials market”

Based on service type, the clinical trials market is segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, decentralized clinical services, clinical trial data management services, medical device testing services, and other services. Laboratory services is the leading segment of the clinical trial services market, this can be attributed to the increasing preference of clinical research professionals to outsource such services.

“Asia Pacific: The fastest-growing region in the clinical trials market.”

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The high growth rate in this region can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, the increasing number of pharmaceutical companies establishing manufacturing facilities in the region, and the lower cost of clinical trials in the region.

“North America: The North America region accounted for the largest share of the clinical trials market”

North America accounted for the largest share of the clinical trials market. Rapid growth in the biosimilar and biologics markets and an increase in clinical trial activity are the major factors driving the market growth.

Competitive Landscape

In 2020, IQVIA (US) dominated the clinical trial market, followed by PPD (US), Syneos Health (US), PRA Health Sciences (US), and LabCorp (US). Other prominent players in the market are WuXi Apptec (China), SGS (Switzerland), and Medpace Holdings (US).

Premium Insights

  • Rising Investments in the Pharmaceutical Industry to Drive the Market Growth
  • Phase III Segment Accounted for Largest Share of North American Clinical Trials Market in 2020
  • Cell-Based Assay Segment Continues to Dominate the Market During the Forecast Period

Market Dynamics

Drivers

  • Increasing Investment in Pharmaceutical R&D
  • Increasing Number of Clinical Trials
  • High Cost of In-House Drug Development
  • Rising Prevalence of Orphan and Rare Diseases

Opportunities

  • Growth in Drugs and Biologics Market Despite COVID-19 Pandemic
  • Rising Demand for Specialized Testing Services Among End-users
  • Need for Novel Clinical Trial Designs for Complex Cell and Gene Therapies

Challenges

  • Shortage of Skilled Professionals for Clinical Trials
  • Requirement of Unique Analytical Testing Approaches for Innovative Drug Molecules

Market Trends

  • Adoption of Artificial Intelligence-Based Tools for Drug Discovery
  • Increasing Outsourcing Activities in Emerging Asian Economies
  • Integrated End-To-End R&D Service Solutions

Ranges/Scenarios

Impact of COVID-19 on Clinical Trials Market

Porter’s Five Forces Analysis

Trends/Disruptions Impacting Customers’ Business

Ecosystem Analysis

Regulatory Analysis

Company Profiles

  • IQVIA
  • Labcorp Drug Development (Covance)
  • Syneos Health Inc.
  • WuXi Apptec
  • Charles River Laboratories
  • Parexel International
  • Pra Health Sciences
  • PPD Inc
  • Icon plc
  • Medpace Holdings Inc
  • ACM Global Laboratories
  • Advanced Clinical
  • SGS
  • Frontage Holdings Corporation
  • PSI CRO Ag
  • Bio Agile Therapeutics
  • Azelix
  • CTserv
  • Pepgra
  • Axcent Advanced Analytics (A3)
  • Dove Quality Solutions
  • Firma Clinical Research
  • Celerion
  • Novotech Health Holdings
  • Geneticist Inc.
  • Linical Americas

For more information about this report visit https://www.researchandmarkets.com/r/dd2bvx



Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Business Wire

Recent Posts

Share repurchase programme

[ad_1] Nørresundby, 26 April 2024Announcement no. 23/2024 The Board of Directors of RTX has, cf. company announcement no. 20/2023 dated…

6 days ago

Gyroscope Market Size, Share And Growth Analysis For 2024-2033

[ad_1] Gyroscope Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Gyroscope Global…

6 days ago

Casting Off the Caste System and its Stigma: Empowering the Forgotten Indigenous People of India with Human Rights

[ad_1] ODISHA, India, and LOS ANGELES, Calif., April 25, 2024 (SEND2PRESS NEWSWIRE) — In the 1880s, to call attention to…

6 days ago

Alipay+ Enables Digital Payment of 14 Overseas E-wallets from 9 Countries and Regions in Hong Kong to Support City’s Global Travel Drive

In support of Hong Kong's new mega tourism and commerce drive, Alipay+ now enables users of 14 leading overseas mobile…

6 days ago

Celebrate "Bleach: Brave Souls" Reaching Over 90 Million Downloads Worldwide with "The Future Society Zenith Summons: Cyber" Featuring New Versions of Ulquiorra, Orihime, and Nnoitora

[ad_2] TOKYO, April 26, 2024 /PRNewswire/ -- KLab Inc. announced that its hit 3D action game Bleach: Brave Souls has…

6 days ago

TransAlta Declares Dividends

[ad_1] CALGARY, Alberta, April 24, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC)…

1 week ago